{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:14:41Z","timestamp":1759335281970,"version":"build-2065373602"},"reference-count":7,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jaad.2020.08.002","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T11:58:05Z","timestamp":1596715085000},"page":"1247-1248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Opportunities for better outcomes in patients with hidradenitis suppurativa"],"prefix":"10.1016","volume":"84","author":[{"given":"Dirk M.","family":"Elston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jaad.2020.08.002_bib1","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jaad.2020.07.108","article-title":"Low prescription of tumor necrosis alpha inhibitors in hidradenitis suppurativa: a\u00a0cross-sectional analysis","volume":"84","author":"Orenstein","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2020.08.002_bib2","doi-asserted-by":"crossref","first-page":"e030579","DOI":"10.1136\/bmjopen-2019-030579","article-title":"Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data","volume":"9","author":"Marvel","year":"2019","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.002_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.002_bib4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/ijd.13798","article-title":"Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy","volume":"57","author":"Shanmugam","year":"2018","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.002_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.002_bib6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaad.2018.06.063","article-title":"Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa","volume":"80","author":"Golbari","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.08.002_bib7","first-page":"e13877","article-title":"Immunomodulatory drugs alone and adjuvant to surgery for hidradenitis suppurativa\/acne inversa-A narrative review","author":"Wollina","year":"2020","journal-title":"Dermatol Ther"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220323513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220323513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:58:46Z","timestamp":1759273126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220323513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0190962220323513"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.08.002","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opportunities for better outcomes in patients with hidradenitis suppurativa","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.07.108","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}